Kornimate/medical-research-clean huggingface dataset:
peroperative fluid management in major gynecological cancer surgeries

Conditions: Fluid Overload; Fluid Loss; Perioperative/Postoperative Complications; Acute Kidney Injury

Summary: the aim of this study is to evaluate the effect of perioperative fluid management on postoperative kidney damage in gynecological cancer surgeries. the main question\[s\] it aims to answer are: does fluid management applied with different hemodynamic monitoring methods affect the risk of postoperative aki? in our clinic, three different fluid management strategies are applied depending on the anesthetist experience. acute kidney injury will be evaluated according to the postoperative akin classification of conventional fluid therapy and targeted fluid therapy with noninvasive or minimally invasive monitoring.

our study was designed as a retrospective study. the files of patients over the age of 18 who underwent open abdominal surgery due to asaii and iii gynecological malignancy will be examined retrospectively. patients who cannot be monitored peroperatively and who undergo hipec will be excluded from the study. patients will be divided into 3 groups according to the fluid management strategy and the hemodynamic monitoring used: group 1: patients receiving conventional fluid therapy; group 2: patients receiving targeted fluid therapy with noninvasive monitoring; group 3: patients receiving targeted fluid therapy with minimally invasive monitoring.

Eligibility criteria:
inclusion criteria: * \>18 years * asa ii-iii * those with normal renal function exclusion criteria: * patients in renal insufficiency * patients with perioperative renal, ureter \& bladder invasion * patients in whom perioperative urine monitoring cannot be performed * patients undergoing hipec * patients with missing data

Keywords: akut kidney injury goal directed fluid therapy peroperative fluid management conventional fluid therapy
electroacupuncture for chemotherapy-related cognitive impairment

Conditions: Chemotherapy-Related Cognitive Impairment

Summary: the objective of this trial is to evaluate the effect of electroacupuncture compared to sham acupuncture in preventing crci among breast cancer patients scheduled to undergo chemotherapy.

participants will be randomized to receive either acupuncture or sham acupuncture treatment. both treatments will be administered twice a week, starting one week before chemotherapy and continuing throughout the chemotherapy period. the study outcomes will be evaluated at three time points: baseline (before acupuncture and chemotherapy), during chemotherapy (one day before the third chemotherapy cycle), after chemotherapy (21 days after the last chemotherapy cycle). each cycle typically lasts for 4 weeks.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed with stage i-iii breast cancer 2. scheduled to undergo chemotherapy 3. aged between 18 and 75 years 4. moca score ≥ 26 5. voluntary agreement to participate in the study and sign an informed consent exclusion criteria: 1. demonstrated tumor metastasis or recurrence 2. had a prior history of chemotherapy 3. reported a history of brain tumors, head trauma or stroke 4. were diagnosed with cognitive function-impaired disorders, such as alzheimer's disease 5. were unable to cooperate with testing for any reasons 6. had severe hepatic or renal insufficiency 7. had hemorrhagic disorders, including von willebrand disease, or were taking anticoagulant or antiplatelet medication 8. had an implanted cardiac pacemaker 9. had a history of alcohol abuse or drug addiction 10. were participating in another interventional trial
a study of tak-660 in surgical procedures for people with hemophilia a.

Conditions: Hemophilia A

Summary: this study is about a factor viii medicine called adynovate (tak-660) used during surgery for people with hemophilia a who have low blood levels of factor viii. the aims of this study are as follows: * to check for side effects from tak-660. * to check how well tak-660 controls bleeding when used routinely during surgery and other invasive procedures such as tooth extractions. the study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. during the study, participants will receive infusions of tak-660 during their hospital stay for surgery according to their clinic's standard practice. the study doctors will check for bleeds and side effects from tak-660 from surgery until discharge.


Eligibility criteria:
inclusion criteria: * participants with blood coagulation factor viii (fviii) deficiency who received this drug during surgery or treatment after the start date of this survey. exclusion criteria: * none
molecular characterization of penile cancers in developing countries

Conditions: Penile Squamous Cell Carcinoma

Summary: this study explores penile squamous cell carcinoma (pscc) in brazil, a rare cancer associated with factors like poor hygiene and hpv infection, using next-generation sequencing to investigate its genomic profiles in 24 deceased patients with advanced pscc.

this study focuses on penile squamous cell carcinoma (pscc), a rare cancer that is more prevalent in underdeveloped regions such as africa, asia, and south america, with brazil having one of the highest incidence rates due to socioeconomic factors. pscc is primarily associated with risk factors like poor local hygiene, smoking history, phimosis, and human papillomavirus (hpv) infection. the research aims to understand the genomic profiles of pscc and their correlation with clinical characteristics, particularly in circumcised vs. non-circumcised populations in brazil. the study will employ next-generation sequencing (ngs) on tumor specimens from 23 deceased patients with advanced pscc who received treatment in brazilian cancer sites.

Eligibility criteria:
inclusion criteria: * men ≥ 18 years of age; * diagnosis of locally advanced or metastatic squamous-cell penile carcinoma; * have received at least one treatment for advanced disease (surgery, radiotherapy and/or chemotherapy); * available representative tumor block of formalin-fixed and paraffin-embedded (ffpe) archive, from primary or metastasis; * patients must be already deceased at time of data collection. exclusion criteria: * patients without medical record available (lost, empty or irretrievable clinical information).
interpretations and predictions of patient reported outcomes by breast cancer patients

Conditions: Breast Cancer

Summary: this study will assess how patients' long-term quality of life after different surgical approaches compares to their predicted quality of life.

this study will assess how patients' long-term quality of life after different surgical approaches compares to their predicted quality of life. it will also provide the research team with improved understanding of how patients interact with and prefer to receive qol information. improved understanding of patient predictions and perceptions of information display will allow us to incorporate predicted future pros into the shared decision making process as well as allow us to provide this important information to patients in a meaningful way.

Eligibility criteria:
inclusion criteria: * pre-surgical female breast cancer patients * female breast cancer survivors exclusion criteria: -
incidence of major complication in case of thoracic aortic aneurysm

Conditions: Thoracic Aortic Aneurysm

Summary: thoracic aneurysm is a silent disease with a potential mid-term high risk of death or major complications. few data are available on the real incidence of major complications in case of small and moderate thoracic aneurysm. different factors are supposed to increase the risk of aortic enlargement as high blood pressure and sleep disorder breathing. the modality of imaging and clinical follow-up are well defined. in this prospective observational study, the aim to assess the incidence of of major complications during follow-up in a population of patients with a small or moderate thoracic aneurysm. the study will also try to identify systemic factors influencing aneurysm evolution.


Eligibility criteria:
inclusion criteria: * documentation of an aortic root aneurysm \> 40 mm * agreement to participate to a longitudinal study and available for a 5 years follow-up exclusion criteria: * presence of comorbidities or pathology with a prognosis of less than 1 year * personal or family history of genetically documented elastic tissue disease or patient meeting the gand clinical criteria suggestive of marfan disease * high-grade mitra-aortic valve disease, even if asymptomatic * unbalanced hypertension ≥ 180/110 mmhg * aneurysm (regardless of thoracic or abdominal location) ≥ 50 mm * aneurysm (regardless of thoracic or abdominal location) with documented progression of more than 5 mm over one year * history of aortic surgery or endovascular intervention and history of type b aortic dissection of medical treatment * renal insufficiency on dialysis, or gfr\< 30 ml/mn (ckd-epi)

Keywords: thoracic aortic aneurysm incidence nocturnal hypertension sleep apnea
quantifying the presence of lung disease and pulmonary hypertension in children with sickle cell disease

Conditions: Sickle Cell Disease

Summary: the proposed research study is a cross-sectional study enrolling young children with sickle cell disease between 5 and 12 years of age. they will be screened as outpatients for consent to perform pulmonary function testing (pft) and echocardiography. in addition, the degree of bronchodilator response will be assessed at each session. to estimate presence of pulmonary hypertension, echocardiography will be performed at the time of pft measures. study design: 1. enroll children aged 5 to 12 years of age with sickle cell disease (hbss, hbsc, hbs beta plus thalassemia, hbs beta zero thalassemia, and hbs oarab) who are established patients within the duke pediatric sickle cell clinic. 2. perform a chart review of all enrolled subjects to obtain specific details regarding birth history, nutritional status (weight, height), family history, sickle cell genotype, parental smoking history, recent laboratory parameters, parental smoking history, any concurrent conditions (atopy, asthma, airway anomaly), history of sickle cell complications and prescribed medications. 3. perform spirometry and plethysmography with the administration of albuterol. 4. before or after completion the pft session, the patient will have echocardiography in the pft lab area 5. using medical record information, determine number of hospitalizations for any pulmonary symptoms indicative of acute chest syndrome (acs) (dyspnea, fever, wheezing, hypoxia, cough, chest pain). in addition, we will track any respiratory or cardiac symptoms or therapies for each subject 6 years after enrollment up to age 18 years using the registry. 6. as standard of care, refer any child identified as having lung disease or pulmonary hypertension to a pediatric pulmonologist and/or cardiologist for monitoring, treatment and ongoing care.


Eligibility criteria:
inclusion criteria: * children aged 5 to 12 years of age with sickle cell disease (hbss, hbsc, hbs beta plus thalassemia, hbs beta zero thalassemia, and hbs oarab) * established patients within the duke pediatric sickle cell clinic. * subjects must have been full-term at birth * any race or gender exclusion criteria: * significant chromosomal/congenital anomalies * hemodynamically significant congenital heart disease (arrhythmia requiring medication, defects with chronic hypoxia, single ventricle physiology, heart failure) * any child within 3 weeks of a respiratory tract infection, an asthma attack, an episode of acs or of a vaso-occlusive or hemolytic crisis.

Keywords: sickle cell disease pulmonary hypertension airway hyperreactivity acute chest syndrome
the anemia control program: early intervention

Conditions: Iron Deficiency Anemia

Summary: the purpose of this study was to determine if a home-based intervention to foster child development improved behavior and development in infants with ida.

iron-deficiency anemia (ida) is associated with alterations in infant behavior and development that may not correct with iron therapy. the purpose of this study was to determine if a home-based intervention to foster child development improved behavior and development in infants with ida. ida and non-anemic infants were randomly assigned to a year of intervention or surveillance only. infants were enrolled and began study participation at 6 or 12 months. all infants were treated with oral iron and visited weekly to record iron intake, feeding, and health (surveillance). for infants randomized to intervention, the weekly home visit included an hour-long program fostering child development by supporting the mother-infant relationship. psychologists, unaware of iron status or intervention assignment, assessed cognitive, motor, and social-emotional development (bayley scales) at the beginning, midpoint, and end of the year.

Eligibility criteria:
inclusion criteria: * birth weight \>= 3.0kg * singleton full-term birth * routine vaginal delivery * no major congenital anomalies * no major perinatal complications * no photo therapy * no hospitalization for longer than 5 days * no chronic illness * no iron therapy * from 1991-94, infants on \>= 250 ml/day cow milk or formula * from 1994-96, infants could be on \< 250 ml/day cow milk or formula * infants identified as anemic at 6 or 12 months and randomly selected nonanemic infants at 6 and 12 months exclusion criteria: * residence outside 4 contiguous working-class communities on outskirts of santiago, chile * another infant \<12 months in household * infant in child care * illiterate or psychotic caregiver or no stable caregiver available to accompany the child for appointments. * until mid-1994, "exclusive" breastfeeding, defined as \>250 ml/d cow milk or formula

Keywords: iron deficiency anemia infant behavior infant development
insomnia in primary care

Conditions: Insomnia

Summary: the goal of this clinical trial is to learn if training primary care providers on treatment of insomnia can improve insomnia symptoms in patients. researchers will compare insomnia symptoms of patients receiving care from trained practices with patients receiving care from control practices (providing care-as-usual), to see if the training helps to provide improved insomnia care. participants will be asked to complete four questionnaires and some participants will be invited for an insomnia consultation in primary care by their primary care providers (pcp).


Eligibility criteria:
inclusion criteria for a patient to be eligible to participate in this study: 1. patient registered with a participating primary care facility and willing to provide informed consent and 2. survey confirmed presence of insomnia symptoms at least 3 times a week during at least the last 3 weeks and 3. survey shown increased score on the insomnia severity index (isi ≥ 11) and 4. survey shown interference with daily functioning on the insomnia severity scale. exclusion criteria: patients meeting any of the following criteria in the survey will be excluded from participation in this study: 1. shift work for individuals awakening outside the hours 4:00 a.m. and 10:00 a.m. or going to bed outside the hours of 8:00 p.m. and 2:00 a.m. more than twice a week 2. other sleep-wake disorders including chronic obstructive sleep apnea, bruxism and narcolepsy, restless leg syndrome and parasomnia. 3. current pregnancy 4. presence of epilepsy, schizophrenia, bipolar disorder, post-traumatic stress disorder or dementia in medical history

Keywords: primary care
relative bioavailability study of four experimental formulations for alzheimer's disease

Conditions: Alzheimer's Disease; Healthy

Summary: the purpose of this study is to assess the bioavailability of four experimental formulations relative to the current reference formulation used in the phase 2 study.


Eligibility criteria:
inclusion criteria: * young healthy male subjects exclusion criteria: * women
the effect of probiotics on exacerbation of inflammatory bowel disease exacerbation (crohn's disease)

Conditions: Crohn's Disease

Summary: inflammatory bowel disease (ibd) is an immune mediated chronic intestinal condition. it includes ulcerative colitis (uc) and crohn's disease(cd). probiotics have been shown to be effective in varried clinical conditions ranging fron infantile diarrhea, necrotizing enterocolitis,helicobacter pylori infections, etc.

this is a prospective study that will enroll 50 patients with crohn's disease.each patient will get the study medication for 6 weeks and will be evaluated twice- before enrollment and after 6 weeks of treatment.

Eligibility criteria:
inclusion criteria: * patients with crohns' disease who are stable or have mild acute exacerbations that do not necessitate treatment with systemic corticosteroids exclusion criteria: * pregnant women, under 18 years or over 60 years, * patients with known ulcerative colitis, * patients with any cancer, * patients with heart failure

Keywords: crohn's disease, endothelial progenitor cells, probiotic
immediate vs. deferred empirical antifungal treatment with voriconazole in neutropenic patients

Conditions: Possible Fungal Infection

Summary: a well-known side-effect of cytostatics (drugs against malignancies) is a decrease in the number of white blood cells, especially of the so-called neutrophil granulocytes, which are very important for the defense against infections. hence their decrease (called "neutropenia") leads to a predisposition to infections. since infections during neutropenia can be very dangerous, the patients are treated with antibiotics from the very first signs of such an infection (usually fever). if the antibiotics (drugs against bacteria) do not lead to a normalization of the body temperature within four days, a drug against fungi is added. in the idea study, one half of the patients receive the antifungal drug voriconazole (as usual) only in case the antibiotics alone do not lead to a normalization of the body temperature (current standard of care). the other half of the patients receive voriconazole immediately after onset of fever (concomitantly with the antibiotics). the research question is, whether in the "early-treatment" group fewer manifest fungal infections will be observed than in the "late-treatment" group.


Eligibility criteria:
inclusion criteria: * acute leukemia, aggressive lymphoma, bone marrow or stem cell transplantation; * neutropenia (\<500 neutrophils/µl) of at least 10 days; * newly diagnosed fever; * positive panfungal polymerase chain reaction assay exclusion criteria: * documented bacterial infection during screening or at randomization * fungemia or other documented invasive fungal infection during screening or at randomization.

Keywords: neutropenia fever of unknown origin empirical treatment voriconazole
choco-cabana trial

Conditions: Atherosclerosis

Summary: the study will be performed 120 patients at about 6 to 8 study centers. only patients with clinical conditions requiring assessment of patency of the treated btk lesions at 6 months post procedure by mra as part of standard care to prevent amputations as consequence of non-detected re-stenosis/occlusions will be included in the study. the sequence in which the individual patients will be treated will be randomized with the chocolate pta balloon and the uncoated conventional pta balloon at each center. 60 patients will be randomized to uncoated conventional pta balloon treatment and 60 patients to treatment with the chocolate pta balloon. all lesions in each patient (lesions that fulfill the inclusion/exclusion criteria) should be treated as the patient is randomized. in patients with long lesions more than one balloon may be used. overlapping of balloons (at least 10mm) is mandatory to avoid untreated gaps between sequential treatments. follow up will be performed at 1 and 6 months.


Eligibility criteria:
inclusion criteria: 1. \>18 years of age 2. chronic stenotic or occlusive atherosclerotic disease of the infrapopliteal arteries 3. patients with clinical conditions requiring assessment of vessel patency of treated btk lesion 6 months post procedure as part of clinical standard of care to prevent amputa-tions as consequence of non-detected re-stenosis 4. btk intervention with lesions between 1 and 25 cm 5. sufficient outflow of the treated artery to the foot (less than 50% stenosis or sufficient collaterals) 6. all btk lesions either to be treated with conventional pta or with the chocolate pta balloon (if inclusion criteria 4 and 5 apply)\* \* the longest lesion will be taken as primary lesion. all other lesions will be also analyzed within the study protocol but separately evaluated. if a secondary lesion does not fulfill the inclusion criteria 4 and 5, the lesion can be treated upon the decision of the operator and will not be analyzed within the study protocol. 7. rutherford 3-5 patients 8. patients who are able to be followed to assess vessel patency according to standard lo-cal hospital care (e.g. dus, mra) 9. successfully treated inflow lesions up to tasc b exclusion criteria: 1. acute or sub-acute thrombosis 2. in-stent restenosis 3. rutherford 1-2 and 6 4. patient who is not fit for follow-up (including contraindication for mra) 5. vessel preparation with cutting balloon, lithotripsie, atherectomy